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ABSTRACT.
We have investigated the expression and role of galectin-1 and other galectins in psoriasis and in the Th1/Th17 effector and dendritic cell responses associated with this chronic inflammatory skin condition. To determine differences between psoriasis patients and healthy donors, galectins expression was analyzed by RT-PCR assays in skin samples and specifically on epidermal and peripheral blood dendritic cells by immunofluorescence and flow cytometry.
In skin of healthy donors galectins 1, 3 and 9 were expressed in a high proportion of Langerhans cells. Also, galectins were differentially expressed in peripheral blood dendritic cell subsets; galectin-1 and galectin-9 were highly expressed in peripheral myeloid dendritic cells compared with plasmacytoid dendritic cells. We found that non-lesional as well as lesional skin samples from psoriasis patients had low levels of galectin-1 at mRNA and protein level in parallel with low levels of IL-10 mRNA compared with skin from healthy patients. However, only lesional skin samples expressed high levels of 
INTRODUCTION.
Galectins are a family of highly-conserved glycan-binding proteins. Although initially described as mediators of developmental processes, members of the galectin family are now known to play important roles in the innate and adaptive immune responses [1, 2] .
Growing evidence indicates that galectin-1 (gal-1) functions as a negative regulator of the inflammatory response. In vitro studies revealed that gal-1 limits the immune response, for example promoting apoptosis of Th-1 cells, inducing IL-10, or down-regulating pro-inflammatory cytokines [3, 4] .
Exogenous gal-1 has immunosuppressive and anti-inflammatory effects in experimental models of inflammation and autoimmunity such as inflammatory bowel disease, autoimmune retinal disease, autoimmune diabetes, and collagen-induced arthritis [5] [6] [7] [8] . In addition, gal-1-deficient mice show augmented Th1 and Th17 responses and enhanced susceptibility to autoimmune neuroinflammation [3] .
Similarly to gal-1, gal-9 down-regulates Th-1 and Th17 responses, and is involved in the suppression induced by CD4+ CD25+ regulatory T cells through its interaction with the Th-1-specific cell surface molecule TIM-3 [9, 10] . Studies in models of inflammatory disease, such as complex immune-induced arthritis, allergic asthma and diabetes, support an anti-inflammatory role for gal-9 [10] [11] [12] . Unlike gal-1, gal-3 can both positively and negatively regulate the inflammatory response, depending on factors such as the specific inflammatory conditions or the type of target cell [13] .
Experimental evidence indicates an involvement of Th1 and Th17 responses in the pathogenesis of psoriasis [14] , a chronic inflammatory skin disease affecting 2 to 3% of the human population. Moreover, a recent study described a beneficial effect of gal-9 treatment in a model of IL-23-induced, psoriasis-like skin inflammation [15] . To examine the potential role of galectins in the immunopathogenesis of psoriasis, we analyzed the expression of gal-1, gal-3 and gal-9 in psoriasis patients, and related this to the levels of Th1/Th17 cytokines. We show that expression of gal-1 is decreased both in epidermal dendritic cells (DCs) and in peripheral blood myeloid DCs (PBDCs) from these patients. Functional assays showed that gal-1 inhibits the Th1 response in cocultures of monocyte-derived DCs (moDCs) from psoriasis patients with autologous peripheral blood lymphocytes.
MATERIAL AND METHODS

Study subjects and sample collection
The study was approved by the institutional review board and the independent ethics committee of the Hospital Universitario de la Princesa, and conformed to the Declaration of Helsinki principles. After giving informed consent, 10 healthy individuals and 24 untreated patients with moderate to severe psoriasis were enrolled. Patients recruited to the study had a psoriasis area and severity index (PASI) ≥ 10 or a body surface area (BSA) ≥10%. The following washout periods were established: 14 days for topical corticosteroids, 28 days for conventional systemic treatment including corticosteroids, methotrexate, cyclosporin, acitretin and phototherapy, and 84 days for biologic anti-TNF agents. Skin punch biopsies (10-mm) were obtained from lesional plaque-type psoriatic skin and non-lesional skin. Biopsies from non-lesional skin were at least 5 cm from a lesional plaque, and were taken preferentially from non sun-exposed areas. In some cases 20 ml of venous peripheral blood were obtained. Normal skin and peripheral blood samples were obtained from 10 surgical patients without cutaneous disease. Data regarding gender, age, duration of psoriasis and clinical disease severity (PASI and BSA) are presented in Table 1 .
RT-PCR analysis of cytokines and lectins
Total RNA was isolated using TRIzol reagent (Invitrogen). One microgram of RNA was used to generate cDNA. IL-17a, IL-21, IL-23, IL-12b, IL-10, IL-27, gal-1, gal-3, gal-4, gal-8, gal-9, dectin-1, DCIR and CLEC5A were amplified using the Power SYBR green PCR master mix (Applied Biosystems, Warrington UK). mRNA was normalized to GAPDH levels. Primer sequences are shown in Table   2 . 
Coculture of moDCs with autologous PBLs.
MoDCs from psoriasis patients preloaded with SEE (0.1 µg/ml) were cocultered with autologous PBLs (1:10) in the presence or absence of h gal-1 (2 µM) for 5 days. Cells were harvested and intracellular levels of IFN-gamma were analyzed in T cells using flow cytometry.
Flow cytometry and cell sorting.
To analyze galectin surface expression on primary circulating DCs, PBMCs were stained with the following mouse anti-human monoclonal antibodies:
PerCP-HLA-DR, FITC-CD3, FITC-CD14, FITC-CD16, FITC-CD19, FITC-CD20, PE-CD123 and V450-CD11c, and goat polyclonal anti-gal-1, anti-gal-3 or antigal-9 followed by Alexa fluor 647-DAG. Myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) were isolated from PBMCs by cell sorting in a FACSAria cell sorter.
DCs were lysed and galectin expression determined by western blot.
Epidermal and dermal single-cell suspensions from healthy skin donors were obtained after separation of the epidermis and dermis as described [16] . Skin cell suspensions were stained with the following antibodies: FITC-HLA-DR and PE-anti-CD1a, and anti-gal-1, anti-gal-3 or anti-gal-9 followed by Alexa fluor 647-DAG for epidermal cells and Pacific blue-CD11c, Pacific orange-CD45, FITC-HLA-DR for dermal cells. Dead cells were excluded using 7 ADD.
Statistical analysis.
Data were analyzed with GraphPad Prism (GraphPad Software Inc, San Diego, USA). The Kruskall-Wallis test and Mann-Whittney U-test were used when appropriate. Spearman test was used for correlation analysis. Differences were considered significant at p<0.05.
RESULTS.
Galectin expression is defective in psoriatic skin
To explore the potential role of galectins in the immunopathogenesis of psoriasis, we conducted an RT-PCR analysis of the expression of gal-1, gal-3, gal-4, gal-8 and gal-9 and the lectins DCIR, CLEC5A and dectin-1 in nonlesional and lesional skin samples from 24 psoriasis patients and control samples from 10 healthy subjects. Compared with the skin of healthy subjects, lesional and non-lesional skin biopsies from psoriasis patients showed low expression of gal-1 mRNA (Fig. 1A, p<0 .05). Levels of gal-3 and gal-4 were also low in lesional skin, but expression in non-lesional (asymptomatic) samples was similar to the level in skin from healthy patients. In contrast, gal-8 and gal-9 expression was similar in all three types of sample ( Fig 1A) . Dectin-1 was detected at high level in lesional skin, in agreement with a recent report [17] .
Conversely, we did not observe differences in the expression of CLEC5A and DCIR.
Increasing evidence suggests that effector Th1 and Th17 cells are key players in the pathogenesis of psoriasis [18] . In order to validate our skin samples, we analyze the mRNA expression of Th1 and Th17 cytokines. RT-PCR analysis revealed high expression of IL-17a, IL-21, IL-12b, IL-23 of in lesional skin of psoriasis patients compared with both non-lesional skin and skin samples from healthy donors (p<0.05 Fig. 1B and supplemental Fig. 1 ). We found higher IL-27 mRNA expression in lesional skin of psoriasis patients than in skin samples from healthy donors (Supplemental Fig. 1 ), according to previous data [19] . IL-27 expression was also above in asymptomatic skin from psoriasis patients, but this difference was not statistically significant. In contrast, expression of the anti-inflammatory cytokine IL-10 was low in lesional and non-lesional skin from psoriasis patients compared with healthy donor skin (p <0.05, Fig. 1B ).
Statistical analysis showed that low levels of gal-1 are associated with high levels of IL-17 (p=<0.0001, r2=0,463), and with low levels of IL-10 (p=<0.0001, r2=0,393) (Fig. 1C) .
Gal-1, gal-3 and gal-9 are expressed in Langerhans cells.
Dendritic cells are central participants in immune mechanisms, and abnormal activation and function of DCs are associated with several chronic inflammatory conditions, including psoriasis [20] . Despite the importance of galectins in immune response regulation, there has been little study of their role in human primary DCs. To study the immune regulatory function of gal-1, gal-3 and gal-9 in psoriasis, we examined their expression on skin DCs.
Immunofluorescence analysis of MHC class-II+ cells in skin sections from healthy subjects revealed expression of gal-1 and gal-9 in MHC class-II+ stellate cells within the epidermis of healthy individuals, pointing to expression on Langerhans cells (LCs) (Fig. 2A) . Gal-3 and gal-7, a galectin characteristic of keratinocytes [21] , were highly expressed on epidermal keratinocytes (Fig. 2A) . 
Gal-1 expression is reduced in Langerhans cells from psoriasis patients
Double-immunofluorescence staining of skin sections from psoriasis patients showed weak staining of gal-1 on epidermal CD1a+ cells in comparison with healthy donors. To quantify this difference, we measured the mean fluorescence intensity of gal-1 staining on CD1a+ epidermal cells in skin sections from eight psoriasis patients and eight healthy subjects. (Supplemental Fig. 2A ). This analysis showed that levels of gal-1 are lower in epidermal CD1a+ DCs from lesional and non-lesional skin from psoriasis patients compared with healthy donor skin (p<0.05) (Supplemental Fig. 2B) . Recently, it has been described that a subpopulation of inflammatory dendritic epidermal cells (IDECs) are CD1a+ [16] . In order to assess the expression of gal-1 specifically in LC, three-color immunostaining was performed in skin samples (Fig. 3A) . The analysis of gal-1 expression showed that Langerhans cells (langerin+ CD1a+) from psoriasis patients express low levels of Gal-1 compared with healthy donors (Fig. 3B) . The low levels of gal-1 were also corroborated in total lysates of skin biopsies from 2 patients and 2 healthy donors by western blot (Fig. 3C) .
Gal-1 expression in other populations of skin DCs.
Due to the lower expression of gal-1 in CD1a+ cells, we analyzed whether there was a differential expression between IDEC CD1a+ and Langerhans cells. The analysis of gal-1 expression in four-color immunostaining (MHC class-II, CD1a, langerin and gal-1) from lesional psoriatic skin revealed that IDECs express very low levels of gal-1 (Fig 4A) .
Beside LC, dermal DCs (dDCs) are the other major population of skin DC in healthy skin [22] . An additional population of inflammatory dermal DCs (CD11c+) has been recently described in patients with psoriasis [23] . The analysis of galectin expression on dDCs by flow cytometry of DCs derived from healthy donor skin showed a mild expression of gal-1 and gal-9 ( Fig. 4B and data not shown). Three-color immunostaining (MHC class-II, CD11c and gal-1) of skin samples from psoriasis patients and healthy donors corroborated the low expression of gal-1 in dDCs in healthy donors (Fig. 4C) and showed an even lower expression in psoriasis patients (Supplemental Fig. 3) Galectins are differentially expressed in peripheral DC subsets, and gal-1 expression is defective in peripheral DCs of psoriasis patients Like skin, peripheral blood contains distinct DC populations. The main PBDC subsets are myeloid DCs (mDCs, CD11c+) and plasmacytoid DCs (pDCs, CD123+) [24] . These subsets differ in their origin, surface markers, and functions [25] . FACS analysis of galectin expression in PBDCs from healthy donors revealed higher surface expression of gal-1, gal-3 and gal-9 on the surface of mDCs compared with pDCs (Fig. 5A) . In contrast, the immunoregulatory molecules ICOS and ICOSL showed no significant differences in expression. Higher expression of gal-1 and gal-9 in mDCs was also detected by western blot of mDCs and pDCs isolated from peripheral blood by cell sorting. We next determined whether galectin expression on peripheral blood mDCs was affected in psoriasis. Flow cytometry analysis revealed significantly lower gal-1 expression on mDCs from psoriasis patients (Fig. 5B) .
Correlation analysis between disease activity (PASI) and gal-1 expression in mDCs showed that higher disease activity indexes are associated with lower levels of gal-1 ( Fig. 5C ; r2=-0.5662, p=0.03). Expression of gal-3 and gal-9 was also slightly lower, but these differences were not statistically significant. Levels of ICOS and ICOSL were similar in psoriasis patients and healthy subjects. To determine whether the reduced expression of gal-1 was also observed in other inflammatory skin condition, gal-1 was analyzed in peripheral mDCs from patients with atopic dermatitis. Our results showed that expression of gal-1 in mDCs from atopic patients is similar to the expression observed in healthy subjects (Fig 5D) .
Inhibition of galectin binding increases IFN-gamma production and decreases IL-10 production by CD4+ T cells
Gal-1 and gal-9 have been described as negative regulators of the Th1 immune response [3] [26] . To assess this, we measured IFN-gamma and IL-10 production in co-cultures of CD4+ T cells with human moDCs preloaded with superantigen staphylococcal enterotoxin E (SEE) in the presence or absence of lactose (50mM), an inhibitor of galectin binding. Intracellular staining revealed that lactose-mediated inhibition of galectin binding augments IFN-gamma production by CD4+ T cells (Fig. 6A) . Conversely, lactose inhibited IL-10 production induced by SEE (Fig. 6A) .
We next probed the ability of gal-1 to regulate IFN-gamma production in cells from psoriasis patients. moDCs from psoriasis patients were preloaded with SEE and co-cultured autologous PBLs. This analysis showed that exogenously added gal-1 inhibited IFN-gamma production by T cells from psoriasis patients (Fig. 6B) . Western blot of total lysates of moDCs from psoriasis patients and healthy donors untreated and treated with LPS showed the lower expression of this protein in cells from psoriasis samples (Fig. 6C) .
DISCUSSION
In this study we show that Langerhans cells and peripheral mDCs from psoriasis patients express low levels of gal-1. In addition, gal-1 is able to reduce the IFN-gamma secretion produced by lymphocytes from these patients.
Current understanding of the exacerbated immune response observed in psoriasis and other inflammatory diseases is based mainly on the study of the upregulation of pro-inflammatory molecules. Accordingly, several components of the pathways involved in T-cell activation are well-established targets in psoriasis antibody-based therapies, for example anti-TNF-alpha, anti-LFA-1, anti-LFA-3, and more recently anti-IL-12/IL-23 [14, 27] . However, recent studies acknowledge the importance of anti-inflammatory signals that counterbalance the inflammatory response. Galectins are implicated in the negative regulation of the immune response, participating in processes such as immune cell proliferation [28] , apoptosis [29] , cellular adhesion and migration [30] [31] [32] , and modulation of the interactions between T cells and APCs [33] .
This study shows that primary human skin DCs express gal-1, gal-3 and gal-9 on their cell surface. Moreover, we detected differential expression of gal-1 and gal-9 in peripheral blood myeloid and plasmacytoid DCs. Although additional studies would be necessary, we could speculate that the differential expression of gal-1 and gal-9 might account for different functions in these cells.
The role of endogenous gal-1 in DCs has recently been studied in a mouse model of encephalomyelitis. Galectin-1, either exogenously supplied or regulated endogenously, drove the differentiation of DCs toward a regulatory function, promoting T cell tolerance [34] [15] . Most evidence pointing to gal-1 as a negative regulator of the immune response has been gathered in animal models of inflammatory diseases, and studies in human disease are comparatively scarce. Here, we demonstrate that psoriasis patients have low expression of gal-1 in peripheral blood myeloid DCs and in LCs of lesional and non-lesional skin that together with previous studies in animal models [34] indicate an important role of gal-1 in the immunopathogenesis of psoriasis. The positive role of gal-1 in IL-10 production has been proposed as one of the mechanisms involved in the inhibition of Th1 and Th17 responses [34] [35] [36] The co-culture experiments showed that galectin inhibition increases IFN-gamma production by CD4+ T cells in response to antigen presentation by DCs, suggesting that galectins also regulate the production of pro-inflammatory cytokines. Interestingly, IFN-gamma production was decreased by addition of recombinant gal-1 to autologous co-cultures of PBLs with moDCs from psoriasis patients. The effects of gal-1 on T cells are likely due to the binding of cellsurface glycoproteins on these cells. A number of T cell glycoproteins, including CD2, CD3, CD7, CD45 and CD43 have been shown to act as receptors for gal-1 binding and to be involved in gal-1-mediated T cell death [37] . However, the absence of apoptosis induction under the doses used in our assays suggests a non-apoptotic mechanism and a gal-1 partner on activated T cells not described yet. It is known that gal-1 is able to modulate the TNF-alpha and IFN-gamma secretion without affect cell viability [38] . The role of galectins in the pathogenesis of psoriasis may also be due to their effect on other cell types. In this regard, gal-1 inhibited keratinocyte migration in a model of wound healing [39] .
Dendritic cells are important for the induction not only of T-cell immunity, but also of tolerance. The maintenance of peripheral tolerance has been proposed to involve LC migration to the draining lymph node during steady state. However, DC tolerogenicity is not specific to a DC subset or restricted to the immature APC state [40] . The means by which DCs convey tolerance are Results are expressed as median (interquartile range). M: male; F: female;
PASI: Psoriasis Area and Severity Index; BSA: Body Surface Area. 
FIGURE LEGENDS. Gal-1 signal intensity was measured on CD1a+ langerin+ cells using ImageJ softaware. Data are means±SD of fluorescence intensity from four psoriasis patients and four healthy controls; at least 50 cells were analyzed for each skin section. C. Gal-1 expression in total lysates of skin biopsies from 2 psoriasis patients (one of them from lesional and non-lesional skin) and 2 healthy donors.
Vimentin expression was used as loading control. 
